Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche gene test for tailored drugs

This article was originally published in The Gray Sheet

Executive Summary

AmpliChip CYP450 pharmacogenomic microarray assay will generate over $100 mil. in revenue by 2008, Roche predicts. Launched as an analyte-specific reagent for CLIA-certified labs June 25, the test is the first pharmacogenomic microarray for clinical applications. Designed to detect variations in genes that play a role in how the body metabolizes drugs for conditions such as cardiovascular disease, high blood pressure, depression and ADHD, the test can facilitate drug and dosage selection and help avoid adverse reactions, Roche says. Approval as an in vitro diagnostic is expected in 2004. Furthering the creation of an "individualized medicine market," the firm says it plans to develop additional microarray diagnostics in the areas of HIV resistance genotyping, p53 cancer resequencing, colorectal cancer risk prediction, cystic fibrosis and human papilloma virus genotyping. The effort stems from a $70 mil. January pact to combine Roche PCR technology with Affymetrix' microarray platform (1"The Gray Sheet" Feb. 10, 2003, p. 6)...
Advertisement

Related Content

Affymetrix GeneChip Arrays Elevated In Roche Pact, Considered By FDA
Affymetrix GeneChip Arrays Elevated In Roche Pact, Considered By FDA
Advertisement
UsernamePublicRestriction

Register

MT018640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel